Atezolizumab Trial in Endometrial Cancer - AtTEnd

PHASE3CompletedINTERVENTIONAL
Enrollment

549

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

January 20, 2025

Study Completion Date

January 20, 2025

Conditions
Endometrial Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).

DRUG

Placebos

Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).

DRUG

Paclitaxel

Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.

DRUG

Carboplatin

Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.

Trial Locations (93)

Unknown

Royal Adelaide hospital, Adelaide

Border Medical Oncology Research Unit, Albury

Icon Cancer Centre, Auchenflower

Pindara Private Hospital, Benowa

Box Hill Hospital, Box Hill

Frankston Hospital, Frankston

Gosford Hospital, Gosford

Royal Brisbane and Women's Hospital, Herston

Royal Hobart Hospital, Hobart

Liverpool Hospital, Liverpool

Northern Cancer Institute, Saint Leonards

Darling Downs Hospital and Health Service - Toowoomba Hospital, Toowoomba

Calvary Mater Newcastle, Waratah

Wollongong Hospital, Wollongong

Medizinische Universitaet Graz - Universitätsklinik für Frauenheilkunde und Geburtshilfe, Graz

Medical University of Innsbruck, Innsbruck

Charité Universitätsmedizin Berlin, Berlin

Kliniken Essen Mitte, Essen

UniversitätsKlinikum Heidelberg, Mannheim

Klinikum der Ludwig-Maximilians-Universität München (LMU), München

AO SS Antonio e Biagio e Cesare Arrigo, Alessandria

Policlinico S. Orsola Malpighi, Bologna

Azienda Sanitaria dell'Alto Adige, Bolzano

ASST degli Spedali Civili di Brescia, Brescia

Fondazione Poliambulanza, Brescia

AOU Cagliari, Policlinico Universitario, Cagliari

AOU Careggi, Florence

ASST di Lecco, Lecco

Ospedale San Luca, Lucca

Istituto Europeo di Oncologia, Milan

Ospedale San Gerardo, Monza

Istituto Oncologico Veneto (IOV), Padua

AOU di Parma, Parma

AOU Pisana, Pisa

AO Arcispedale Santa Maria Nuova, Reggio Emilia

Ausl Romagna, Rimini

"Policlinico Umberto I, Università di Roma La Sapienza", Roma

Ospedale di Sondrio ASST Valtellina e Alto Lario, Sondrio

Ospedale SS Trinità, Sora

AO Ordine Mauriziano, Torino

AOU Città della Salute e della Scienza di Torino - Ospedale Sant'Anna, Torino

P.O Sant'Andrea Vercelli, Vercelli

Hirosaki University Hospital, Aomori

National Cancer Center Hospital East, Chiba

Shikoku Cancer Center, Ehime

Kurume University Hospital, Fukuoka

Hokkaido University Hospital, Hokkaido

Tohoku University Hospital, Miyagi

Niigata University Medical&Dental Hospital, Niigata

Osaka University Hospital, Osaka

Shizuoka Cancer Center, Shizuoka

Keio University Hospital, Tokyo

Auckland city Hospital, Auckland

Keimyung University Dongsan Medical Center, Daegu

Ilsan Cha Medical Center, Gyeonggi-do

Seoul National University Bundang Hospital, Gyeonggi-do

Gachon University Gil Medical Center, Incheon

Asan Medical Center, Seoul

Gangnam Severance Hospital, Seoul

Konkuk University Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul St. Mary's Hospital, Seoul

Severance Hospital, Seoul

Hospital De Sant Pau I La Santa Creu, Barcelona

Hospital Universitario Vall d´Hebron Institute of Oncology (VHIO), Barcelona

Institut Català d'Oncologia (ICO) Girona, Girona

Institut Català d'Oncologia (ICO), L'Hospitalet- Hospital Duran I Reynals, L'Hospitalet de Llobregat

Hospital 12 de Octubre, Madrid

Hospital Universitario La Paz, Madrid

MD Anderson Cancer Center, Madrid

Hospital Universitario Central de Asturias, Oviedo

Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela

Hospital Universitario Miguel Servet Zaragoza, Zaragoza

Kantonsspital, Baden

Universitätsspital, Basel

IOSI, Bellinzona

Inselspital, Bern

Kantonsspital, Lucerne

Frauenfeld, Münsterlingen

Kantonsspital, Winterthur

Universitätsspital, Zurich

Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung City

Chang Gung Memorial Hospital-Linkou, Taoyuan

Royal Derby Hospital, Derby

Royal Devon & Exeter Hospital, Exeter

Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow

Velindre Cancer Centre, Glasgow

Imperial College Healthcare NHS Trust, London

Royal Marsden Hospital, London

St Bartholomew's Hospital, London

The Christie NHS Foundation Trust, Manchester

NUHT - Nottingham University Hospital NHS Trust, Nottingham

Derriford Hospital, Plymouth

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT03603184 - Atezolizumab Trial in Endometrial Cancer - AtTEnd | Biotech Hunter | Biotech Hunter